TABLE 2.
Univariate and multivariable regression analysis for major complications
| Variable | Univariate logistic regression | Multivariable logistic regression | ||
|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |
| All histologies | ||||
| Age | ||||
| < 65 years | Reference | Reference | ||
| ≥ 65 years | 1.66 (1.12–2.46) | 0.01 | 1.72 (1.08–2.75) | 0.02 |
| Gender | ||||
| Female | Reference | |||
| Male | 1.01 (0.73–1.42) | 0.94 | ||
| Race | ||||
| White | Reference | |||
| Black | 1.44 (0.75–2.79) | 0.27 | ||
| Other | 1.18 (0.69–2.01) | 0.54 | ||
| BMI | ||||
| ≤ 18.5 | Reference | |||
| 18.5–24.9 | 1.04 (0.34–3.15) | 0.95 | ||
| 25–29.9 | 0.91 (0.29–2/76) | 0.87 | ||
| 30–34.9 | 1.06 (0.34–3.31) | 0.93 | ||
| 35–39.9 | 1.11 (0.33–3.71) | 0.86 | ||
| ≥ 40 | 0.67 (0.17–2.63) | 0.56 | ||
| Functional status | ||||
| Independent | Reference | |||
| Partially dependent/totally dependent | 2.03 (0.58–7.09) | 0.27 | ||
| Neoadjuvant chemotherapy | ||||
| No neoadjuvant chemotherapy | Reference | |||
| Received neoadjuvant chemotherapy | 1.18 (0.84–1.66) | 0.35 | ||
| Histology | ||||
| Non-invasive appendiceal | Reference | Reference | ||
| Invasive appendiceal | 1.75 (1.15–2.66) | 0.01 | 2.15 (1.36–3.37) | < 0.01 |
| PCI (median, IQR) | ||||
| PCI < 13 | Reference | Reference | ||
| PCI ≥ 13 | 2.65 (1.86–3.77) | < 0.01 | 2.13 (1.38–3.29) | < 0.01 |
| CCR | ||||
| CCR0 | Reference | Reference | ||
| CCR1 | 2.01 (1.43–2.81) | < 0.01 | 1.58 (0.64–3.92) | 0.32 |
| Non-invasive histology | ||||
| Age | ||||
| < 65 years | Reference | |||
| ≥ 65 years | 1.75 (0.77–3.99) | 0.18 | ||
| Gender | ||||
| Female | Reference | |||
| Male | 0.58 (0.27–1.22) | 0.15 | ||
| Race | ||||
| White | Reference | |||
| Black | 1.50 (0.35–6.36) | 0.65 | ||
| Other | 1.80 (0.61–5.36) | 0.31 | ||
| BMI | ||||
| ≤ 18.5 | Reference | |||
| 18.5–24.9 | 0.84 (0.35–2.03) | 0.49 | ||
| 25–29.9 | 0.95 (0.29–3.10) | 0.90 | ||
| 30–34.9 | 1.69 (0.56–5.19) | 0.25 | ||
| 35–39.9 | 1.07 (0.19–6.10) | 0.95 | ||
| ≥ 40 | 0 (0) | 0.83 | ||
| Functional status | ||||
| Independent | Reference | |||
| Partially dependent/totally dependent | - | - | ||
| Neoadjuvant chemotherapy | ||||
| No neoadjuvant chemotherapy | Reference | |||
| Received neoadjuvant chemotherapy | 0.51 (0.11–2.44) | 0.40 | ||
| PCI (median, IQR) | ||||
| PCI < 13 | Reference | |||
| PCI C 13 | 1.44 (0.67–3.09) | 0.35 | ||
| CCR | ||||
| CCR0 | Reference | |||
| CCR1 | 1.46 (0.71–3.00) | 0.30 | ||
| Invasive histology | ||||
| Age | ||||
| < 65 years | Reference | Reference | ||
| ≥ 65 years | 1.79 (1.05–3.06) | 0.03 | 2.04 (1.16–3.59) | 0.01 |
| Gender | ||||
| Female | Reference | |||
| Male | 1.10 (0.71–1.71) | 0.67 | ||
| Race | ||||
| White | Reference | |||
| Black | 1.25 (0.54–2.89) | 0.60 | ||
| Other | 0.49 (0.23–1.05) | 0.07 | ||
| BMI | ||||
| ≤ 18.5 | Reference | |||
| 18.5–24.9 | 0.91 (0.19–4.3) | 0.91 | ||
| 25–29.9 | 0.79 (0.17–3.68) | 0.76 | ||
| 30–34.9 | 0.94 (0.19–4.54) | 0.94 | ||
| 35–39.9 | 0.74 (0.14–3.99) | 0.73 | ||
| ≥ 40 | 1.67 (0.23–12.22) | 0.52 | ||
| Functional status | ||||
| Independent | Reference | |||
| Partially dependent/totally dependent | 0.38 (0.04–3.39) | 0.38 | ||
| Neoadjuvant chemotherapy | ||||
| No neoadjuvant chemotherapy | Reference | |||
| Received neoadjuvant chemotherapy | 1.15 (0.74–1.79) | 0.54 | ||
| PCI (median, IQR) | ||||
| PCI < 13 | Reference | Reference | ||
| PCI ≥ 13 | 2.90 (1.93–4.61) | < 0.01 | 2.66 (1.62–4.37) | < 0.01 |
| CCR | ||||
| CCR0 | Reference | Reference | ||
| CCR1 | 1.94 (1.24–3.04) | < 0.01 | 1.50 (0.91–2.48) | 0.11 |
Bold values indicate statistical significance with a p value of < 0.05